Importance of Cystatin C Assay Standardization

To the Editor:
Cystatin C is an alternative blood biomarker of kidney function (1, 2 ) . Relatively little effort has been devoted to standardization of cystatin C measurement until recently, when the IFCC formed a working group to produce an international certified cystatin C reference material (ERM-DA471/ IFCC), which was released in June 2010. In the current study, we evaluated a new cystatin C particleenhanced turbidimetric assay (PETIA) 1 (Gentian AS) that is traceable to this certified cystatin C reference material (3 ) and can be routinely run on a chemistry autoanalyzer, therefore potentially increasing availability and decreasing costs (4 ) .
For assay validation, waste patient serum that had been stored for no more than 7 days at 4°C (n ϭ 102) was obtained from the Mayo Clinic Central Clinical Laboratory. We also studied biobanked samples for which cystatin C had been measured by particleenhanced nephelometric assay (PENIA) in 2000 and that had subsequently been stored at Ϫ70°C without any intervening freezethaw cycles. The study was approved by the Mayo Clinic Institutional Review Board.
The Gentian cystatin C PETIA was deployed on a cobas 6000/501c analyzer (Roche Diagnostics) according to the manufacturer's instructions and with reagent kits supplied by Atlantic Diagnostics. Cystatin C was also measured with the Siemens (previously Dade Behring) PENIA, as previously described (3 ) . The ERM-DA471/IFCC reference material was produced by the Institute for Reference Materials and Measurements and was obtained from Analytical Reference Material International (3 ) .
The PENIA and PETIA methods were compared by Passing-Bablok regression analysis; Bland-Altman plots were used for analyzing the difference between these 2 methods. Results were analyzed with the statistical analysis programs Analyse-it (version 2.12; Analyse-it Software), JMP (version 8; SAS Institute, www.sas.com), and Microsoft Excel (version 2003; Microsoft Corporation).
PETIA measurements of cystatin C produced imprecision estimates (CVs) of 0.65% to 1.3% at cystatin C concentrations between 0.98 and 1.88 mg/L. The lower limit of quantification was established at 0.35 mg/L with a CV of Ͻ2% by measuring 3 serum samples with signals just above those of the lowest calibrator 5 times each. Linearity studies of serum and plasma samples and the international standard diluted with water yielded percentages of the measured cystatin C concentration with respect to the expected concentration of 90%-105% over a signal interval of 0.33-5.97 mg/L, thereby setting the upper end of the analytical measurement interval at 6 mg/L. The response was linear and parallel when high-signal serum (1.87 mg/L) and plasma (3.00 mg/L) samples and the certified reference material (5.97 mg/L) were diluted up to 8-fold. To further assess performance, we carried out a study in which we mixed a high-signal patient serum sample (3.05 mg/L) and 3 low-signal serum samples (0.99 -1.29 mg/L) and demonstrated recovery rates of 100%-105% of the predicted value.
When we reanalyzed a subset of samples from the assayvalidation cohort (n ϭ 40) with the PENIA currently deployed in the Mayo Clinic laboratory, we observed an unexpected 25% positive difference for the PETIA method (95% CI, 15%-36%). To further examine this difference between the 2 methods, we reanalyzed biobanked samples from a reference value study of the PENIA carried out at the Mayo Clinic in 2000. Interestingly, the current PENIA results were 19% lower across the measurement interval compared with values obtained in 2000 with the same PENIA platform (Fig. 1) . The difference was in a direction that could account for much of the discrepancy observed between the current PENIA and PETIA results (within the 95% CI). Other laboratories have also recently reported a similar drift in the PENIA assay over time (5 ) . When we combined the data for 142 samples run on both platforms, we observed 23% higher values overall for the PETIA method.
To evaluate this interassay difference further, we reconsti-tuted the certified IFCC cystatin C reference material according to the manufacturer's instructions and then diluted it with 3 volumes of normal saline to obtain a target concentration of 1.38 mg/L, which is well within the expected clinical interval. The Gentian PETIA yielded a cystatin C concentration of 1.35 mg/L (98% of target), with the corresponding PENIA result being 1.10 mg/L (80% of target). Thus, the PETIA, but not the PENIA, yields the expected results for this international reference material.
In conclusion, PETIA can accurately measure cystatin C on a chemistry autoanalyzer. The PETIA had 23% higher values compared with the PENIA currently used in the Renal Function Laboratory at the Mayo Clinic. Using a recently published equation for the estimated glomerular filtration rate (4 ), we find that an increase in the cystatin C concentration from 1.00 mg/L to 1.23 mg/L changes the calculated eGFR from 77 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 to 60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 , whereas a shift from 2.00 mg/L to 2.46 mg/L changes the eGFR from 34 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 to 26 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 . Furthermore, banked samples that had been analyzed by the PENIA in 2000 yielded results that were 19% lower when they were rerun by the same PENIA in 2010. Therefore, this study highlights the importance of standardization if cystatin C is to be more widely used to estimate the GFR and place patients in the correct chronic kidney disease stage.
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Impact of Implementation of the High-Sensitivity Cardiac Troponin T Assay in a University Hospital Setting
To the Editor:
The performance of the highsensitivity cardiac troponin T assay (hs-cTnT) 1 has been evaluated in a multicenter study (1 ) . Effective July 2009, we replaced the fourth-generation troponin T assay (cTnT) with the hs-cTnT assay in clinical practice. This study audits the impact of this implementation.
The hs-cTnT, implemented on the cobas e 411 platform (Roche Diagnostics), fully replaced the cTnT performed on the Elecsys 2010 analyzer [cutoff, 30 pg/mLbased on actual assay performance (10% CV concentration)]. We obtained a detection limit of 5 pg/mL, a 99th percentile of 15 pg/mL, limited comparability with the cTnT at concentrations Ͻ100 pg/mL (on average, a 30-pg/mL cTnT concentration yielded a value of approxi-mately 65 pg/mL with the hs-cTnT) and mean CVs of 9.1% for the cTnT (at 39 pg/mL) and 8.5% for the hs-cTnT (at 17 pg/mL). We retrieved hs-cTnT results for the first 3 months after implementation (July 16 to October 15, 2009) and cTnT results for the same period 1 year previously. Results were dichotomized as positive or negative with respect to cutoffs. Among troponin-positive patients with at least 2 results during their examination, we divided markerrelease curves on the basis of typical or atypical kinetics. We defined as "typical" an increasing or decreasing pattern showing a troponin change between 2 consecutive samples exceeding ϩ46% for increasing troponin results and Ϫ32% for decreasing results. Otherwise, the troponin pattern was considered "atypical." For definition of these percentage changes, we referred to the shortterm biological variation for troponin I (2 ) . We are aware, however, that the 2 cardiac troponins may have different biological kinetics in blood, so their biological variation may be different.
In the evaluated period, 2287 hs-cTnT tests were performed during 1371 examinations of 1137 patients. Correspondingly, 2170 cTnT tests were performed during 1409 examinations of 1205 patients. After hs-cTnT implementation, a 5.4% increase in the hospital-wide test volume was recorded, despite a slight decrease in the number of admitted patients and examinations. The mean (SD) number of troponin tests per examination was 1.54 (1.0) before and 1.67 (1.1) after hs-cTnT implementation (P Ͻ 0.0001), with a single test ordered in 67.5% and 60.2% of examinations, respectively. The distribution of troponin orders and positive-test rates in different wards is shown in Table 1 . A positive result was found in 31.7% of cTnT tests and in 58.7% of hs-cTnT tests (relative difference, ϩ85%), corresponding to 25.3% and 51.6% positive examinations, respectively (P Ͻ 0.0001). Of all the hs-cTnT positive results, 64% fell in the 16 -65 pg/mL interval, previously negative with the cTnT. In the emergency department after hs-cTnT implementation, the number of hospitalized patients with positive troponin results increased from 158 to 292 (ϩ85%), but the rate of admission in intensive care and nonintensive care departments was unchanged (P ϭ 0.108). In the same periods, 16 cTnT-positive patients (8.5%) and 109 hs-cTnT-positive patients (26.6%) were discharged. Of these discharged patients, 1 cTnT-positive patient and 13 hs-cTnT-positive patients were readmitted to the emergency department in the subsequent 2 months (P ϭ 0.804, between the 2 assays).
We audited 458 cTnT and 546 hs-cTnT curves, of which 39.1% and 69.0%, respectively, had at least 1 positive result (P Ͻ 0.0001). The difference in the percentage of positive curves displaying a typical marker release was not significant (17.2% for the cTnT vs 20.5% for the hs-cTnT, P ϭ 0.32). A higher absolute number of typical positive curves was observed after hs-cTnT implementation (from 79 to 112). This increased ability to detect events involving acute marker release was fully explained by the number of typically positive curves in which the hs-cTnT result never exceeded 65 pg/mL (n ϭ 38).
The replacement of the cTnT with the hs-cTnT markedly increased the rate of positive tests. A similar outcome was previously described for a contemporary sensitive troponin I assay (3 ) . What is unique in our experience is the magnitude of the increase in positive results after hs-cTnT introduction, which was based on imple-
